Twist Bioscience Co. (NASDAQ:TWST) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Twist Bioscience Co. (NASDAQ:TWST) has earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating on the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $54.40.

A number of equities analysts recently issued reports on TWST shares. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a research note on Tuesday, February 4th. Barclays set a $58.00 target price on shares of Twist Bioscience and gave the stock an “overweight” rating in a research note on Monday, February 3rd. Wolfe Research assumed coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. JPMorgan Chase & Co. upped their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research report on Tuesday, February 4th. Finally, Robert W. Baird lifted their target price on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th.

Twist Bioscience Trading Down 2.9 %

NASDAQ:TWST opened at $40.36 on Monday. Twist Bioscience has a one year low of $27.41 and a one year high of $60.90. The company’s 50-day simple moving average is $45.15 and its 200 day simple moving average is $45.37. The firm has a market capitalization of $2.41 billion, a P/E ratio of -11.94 and a beta of 2.15. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $88.70 million for the quarter, compared to the consensus estimate of $86.96 million. During the same quarter in the prior year, the business posted ($0.75) EPS. The firm’s quarterly revenue was up 24.1% compared to the same quarter last year. As a group, analysts forecast that Twist Bioscience will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In other news, Director Robert Chess sold 2,940 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $53.13, for a total value of $156,202.20. Following the transaction, the director now owns 18,173 shares in the company, valued at $965,531.49. This represents a 13.93 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Paula Green sold 1,259 shares of the business’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $62,131.65. Following the sale, the senior vice president now owns 132,014 shares of the company’s stock, valued at $6,514,890.90. This trade represents a 0.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 33,799 shares of company stock valued at $1,593,944. 3.01% of the stock is owned by company insiders.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Massachusetts Financial Services Co. MA raised its stake in shares of Twist Bioscience by 215.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock worth $1,324,000 after buying an additional 20,035 shares during the period. Barclays PLC raised its stake in Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after acquiring an additional 104,420 shares during the period. FMR LLC lifted its holdings in Twist Bioscience by 6.0% during the third quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after purchasing an additional 12,327 shares in the last quarter. Avanza Fonder AB bought a new position in shares of Twist Bioscience in the fourth quarter worth approximately $1,059,000. Finally, BNP Paribas Financial Markets increased its stake in shares of Twist Bioscience by 128.1% in the third quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock worth $1,718,000 after purchasing an additional 21,357 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.